Press Releases
Whether it’s a new product enabling ground-breaking research, a strategic partnership with a customer, or a charitable partnership that supports our mission, we’ve always got something going on. Below you’ll find our most recent press releases as well as a filter to further streamline your search.
Contact
For journalist inquiries only, contact:
Rachel Bloom-Baglin
Phone: +978-436-1725
Apr 24, 2024
Apr 17, 2024
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube TourMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.
Apr 16, 2024
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety TestingMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
Feb 28, 2024
Feb 14, 2024
Feb 13, 2024
Press Release Test AEM3-605Teaser text.
Jan 24, 2024
Dec 27, 2023
Dec 27, 2023
Dec 20, 2023
Oct 22, 2023
Oct 10, 2023
Oct 02, 2023
Sep 11, 2023
Aug 29, 2023
Jul 12, 2023
Merck Invests € 23 Million to Expand Cell Culture Media Production in Kansas, USALenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence
Jun 06, 2023
MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech GrantMilliporeSigma announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.
May 31, 2023
Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersAccording to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.
May 31, 2023
Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandResponds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.
May 03, 2023
The Life Science Business of Merck KGaA, Darmstadt, Germany Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South KoreaMilliporeSigma has announced that the Life Science business sector has signed a non-binding MoU) with the Ministry of Trade, Industry and Energy (MOTIE) and Daejeon City for a new Asia-Pacific BioProcessing Center.
Apr 26, 2023
MilliporeSigma Kicks Off 2023 Curiosity Cube Mobile Lab TourOver 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.
Apr 24, 2023
MilliporeSigma Launches Ultimus® Film to Offer Superior Strength and Leak Resistance in Single-use AssembliesMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the launch of its Ultimus® Single-Use Process Container Film.
Mar 27, 2023
MilliporeSigma Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry EducationPartnership to support Beyond Benign’s online learning platform and higher education program
Dec 08, 2022
MilliporeSigma Signs MoU with Synplogen to Accelerate Development and Manufacturing of Viral Vector-based Gene Therapy ApplicationsMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen.
Dec 06, 2022
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMilliporeSigma a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems.
Nov 25, 2022
AEM2-823-PR - - MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-UpMilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Nov 16, 2022
MilliporeSigma Invests € 290 Million in U.S. Drug Safety Testing CapacityMerck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.
Nov 07, 2022
MilliporeSigma Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in ChinaMilliporeSigma, a leading science and technology company, today announced a collaboration with Biotheus.
Nov 01, 2022
Oct 04, 2022
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO ServicesThe Life Science business of Merck KGaA, Darmstadt, Germany, has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France.
Sep 28, 2022
Sep 21, 2022
Sep 21, 2022
MilliporeSigma Announces Opening of New € 29 Million Biologics Testing Center in ShanghaiMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Sep 08, 2022
MilliporeSigma Invests More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, FranceMerck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies
Aug 08, 2022
MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production PlatformMilliporeSigma, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering.
Jul 19, 2022
New Solar Panels at MilliporeSigma’s Wisconsin, USA Site Add Renewable Energy to Power Grid7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces the company’s long-term commitment to renewable energy.
Jul 18, 2022
Life Science Business of MilliporeSigma Breaks Ground on Company’s First Lateral Flow Membrane Production Facility in the United StatesNew facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.
Jun 29, 2022
MilliporeSigma Signs MoU with Lotte Biologics for Biologics ManufacturingMilliporeSigma signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA.
Jun 22, 2022
MilliporeSigma Opens € 59 Million CDMO Facility to Address Demand for Critical Cancer TherapiesMilliporeSigma, announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin.
Jun 14, 2022
MilliporeSigma Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream ProcessingMilliporeSigma collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).
May 23, 2022
MilliporeSigma Invests More Than €440 Million and Expands its Membrane and Filtration Manufacturing in IrelandThe investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.
May 18, 2022
MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile LabMilliporeSigma today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube® mobile science lab in Europe and North America.
Apr 28, 2022
MilliporeSigma Announces Investment of Approximately € 100 Million to Accelerate Single-Use Manufacturing in ChinaMilliporeSigma’s First Asia Pacific Mobius® Single-Use Manufacturing Center in Wuxi, China
Apr 21, 2022
MilliporeSigma Transforms Media Preparation and Dispensing with New ReadyStream® SystemReadyStream® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.
Apr 14, 2022
MilliporeSigma’s ZooMAb® Antibodies Earns First-Ever ACT Label from My Green LabZooMAb® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab
Apr 05, 2022
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing CapabilitiesMilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies.
Feb 23, 2022
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-UpMilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Feb 15, 2022
MilliporeSigma and Waters to Collaborate on Extractables and Leachables Reference LibraryMilliporeSigma's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements
Feb 07, 2022
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future GrowthMilliporeSigma today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
Jan 26, 2022
MilliporeSigma Announces MoU with ID Pharma to Accelerate Development and Manufacturing of Gene TherapyMilliporeSigma, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.
Jan 20, 2022
MilliporeSigma Announces Elevian as Winner of its North American Advance Biotech GrantMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program
Jan 11, 2022
MilliporeSigma Announces Expansion of Stable Isotope Center of Excellence in Miamisburg, OhioMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, today announced the expansion of its Stable Isotope Center of Excellence in Miamisburg, Ohio.
Jan 06, 2022
Definitive Agreement to Acquire Exelead will Strengthen MilliporeSigma’s CDMO Offering for mRNAMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead.
Dec 29, 2021
MilliporeSigma Announces $136.7 Million U.S. Government Contract Award for New Lateral Flow Membrane Production Facility in Sheboygan, WisconsinMilliporeSigma today announced that it has been awarded a $136.7M USD contract award for the construction of a lateral flow membrane production facility over a three-year period at the company’s Sheboygan, Wisconsin site.
Dec 15, 2021
Dec 13, 2021
MilliporeSigma Announces Collaboration with Innovative Biotech to Support Establishment of First Vaccine Production Facility in NigeriaMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the Life Science business sector has signed an agreement with biotechnology company Innovative Biotech.
Dec 13, 2021
MilliporeSigma Announces MoU with SKKU Institute of Quantum Biophysics for In-depth Scientific CollaborationMoU marks steps towards the first industry-academia collaboration for quantum biophysics medicines in South Korea
Dec 11, 2021
MilliporeSigma Announces Conferring of 2021 Young Scientists AwardsAward recognizes early in career scientists for Indonesia-based research
Nov 11, 2021
MilliporeSigma Announces Strategic Agreement with GI Innovation to Facilitate Biomedicine Development in KoreaMilliporeSigma announced that the Life Science business sector signed a Memorandum of Understanding with local bio-venture company GI Innovation.
Nov 09, 2021
MilliporeSigma Announces Leadership Changes in FranceMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the retirement of Jean-Phillipe Maurer as Head of Molsheim Operations, effective December 1.
Nov 03, 2021
MilliporeSigma Announces Support of SaudiVax in Becoming First Developer and Manufacturer of Halal Vaccines and Biotherapeutics in Saudi ArabiaMilliporeSigma today announced that the Life Science business sector will support SaudiVax Ltd. to design a manufacturing facility to localize manufacturing of biologics and vaccines for the MENA region.
Oct 28, 2021
MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) TherapiesMilliporeSigma today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies.
Oct 21, 2021
MilliporeSigma Announces the Commemoration of Fifth Anniversary of M Lab™ Collaboration Center in Songdo, South KoreaKorea M Lab™ Collaboration Center marks five years of continuous operation, recording over 540 collaborations and trainings, benefitting over 1,000 biopharmaceutical and biotech customers
Oct 20, 2021
MilliporeSigma Announces Collaboration with Bio-valley (Beijing) Technology Co., LTD on Biotechnology R&D Platform to Support Talent Development in ChinaMilliporeSigma today announced that the Life Science business sector entered into a collaboration with Bio-valley (Beijing) Technology Co., LTD (Bio-valley) to establish technical talent training programs for China’s biopharmaceutical industry.
Oct 12, 2021
MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene TherapyMilliporeSigma today announced the opening of its second Carlsbad, California-based facility, significantly expanding its CDMO footprint.
Oct 06, 2021
MilliporeSigma’s Danvers Facility Honored as a Manufacturer of the Year by Commonwealth’s Legislative Manufacturing CaucusMilliporeSigma, the U.S. and Canadian life science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, was selected as a Manufacturer of the Year for its Danvers facility at the 6th Annual Manufacturing Awards Ceremony.
Oct 05, 2021
MilliporeSigma Announces the Licensing of Foundational CRISPR Technology to Cellecta, Paving Pathway for Development of Next-Generation TreatmentsMilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, announces that its Life Science business sector has signed an agreement licensing its patented CRISPR-Cas9 technology to California-based Cellecta, Inc.
Aug 27, 2021
MilliporeSigma funds Indian Institute of Technology (IIT) Bombay for Covid-19 researchMilliporeSigma today announced a donation of INR 1.7crore (194,000€) over two years to the Indian Institute of Technology (IIT), Bombay to support the development of clinical tests for Covid-19 disease severity assessment.
Jul 15, 2021
Press Release 0520 MilliporeSigma NA HeadlinePress Release 0520 MilliporeSigma NA Teasser
Jul 05, 2021
MilliporeSigma’s Tokyo M Lab™ Collaboration Center Commemorates Fifth Anniversary of Supporting Science Community in JapanLab marks five years of continuous operation and 400+ activities, benefitting more than 10,000 customers.
Jun 09, 2021
MilliporeSigma Holds Joint Seminar with KOFWST to Address Safe Management of Research LabsMilliporeSigma will hold a collaborative seminar with the Korea Federation of Women’s Science and Technology Associations (KOFWST) about ways to ensure a safe and healthy laboratory environment for pregnant scientists.
May 26, 2021
MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid-19 DemandTo meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule.
May 20, 2021
MilliporeSigma Improves Lab Productivity Through Faster and More Sustainable Nucleic Acid PurificationMilliporeSigma today introduced a new solution improving productivity in the lab through a more flexible and streamlined nucleic acid purification process — GenElute™-E Single Spin purification kits.
May 18, 2021
MilliporeSigma Announces VectorY as Winner of its Advance Biotech GrantMilliporeSigma today announced that VectorY has been selected as the European winner of its 2021 Advance Biotech Grant Program.
May 04, 2021
MilliporeSigma Partners with Topco Scientific Co. to Increase Greener Manufacturing Materials UsageMilliporeSigma today announced a partnership with Topco Scientific Co. (TSC), a leading semiconductor supplier in Taiwan, to increase the use of more sustainable materials for the electronics industry.
May 03, 2021
Press Release Jen 552021 NAPress Release Jen 552021 NA TEASER
Apr 21, 2021
MilliporeSigma Press 4/22 - NAMilliporeSigma Press 4/22 Teaser NA
Apr 15, 2021
Apr 07, 2021
Mar 30, 2021
MilliporeSigma Establishes Collaboration Laboratory with Universitas Indonesia to Advance Life Science ResearchMilliporeSigma today announced a strategic partnership with the Universitas Indonesia (FMIPA-UI) to establish the first Collaboration Laboratory between the company and the university.
Mar 17, 2021
MilliporeSigma Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving TherapiesMilliporeSigma will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Mar 15, 2021
MilliporeSigma Brings New Renewable Energy to the Grid through Virtual Power Purchase Agreement with Enel Green PowerAs part of its ongoing commitment to renewable energy, MilliporeSigma has signed a 12-year, off-site, virtual power purchase agreement with Enel Green Power for the construction of a future wind and storage project in Texas.
Feb 15, 2021
MilliporeSigma Enhances Design for Sustainability Framework, Offers Customers Data-Driven Insights for Greener SolutionsMilliporeSigma has launched an enhanced Design for Sustainability (DfS) framework, a unique approach to holistically integrate sustainability into products, systems and services.
Feb 12, 2021
Feb 04, 2021
Test for Teaser PRTest for Teaser PR NA
Feb 04, 2021
MilliporeSigma Continues Commitment to Science Education and Equity with Leading Non-Profits Around the WorldBuilding on its commitment to accelerate scientific research and science education, MilliporeSigma has announced seven expanded partnerships with leading nonprofit organizations across the world.
Jan 08, 2021
Headline MilliporeSigmaTeaser Headline MilliporeSigma
Jan 07, 2021
MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments, and DiagnosticsMilliporeSigma today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO).
Dec 07, 2020
MilliporeSigma Expands Production CapacitiesMilliporeSigma today announced the broadening of its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.
Nov 20, 2020
Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany Named to The Boston Globe’s ‘Top Places to Work’ ListMerck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its Massachusetts-based businesses, MilliporeSigma, EMD Serono, and EMD Performance Materials, have again been named to The Boston Globe’s annual “Top Places to
Nov 10, 2020
MilliporeSigma’s Latest Technologies Earn Industry Recognition for Accelerating Bioprocessing 4.0MilliporeSigma today announced that its first-to-market Blazar™ platform from the BioReliance® portfolio has won R&D 100 and CPhI Awards for its ability to reduce testing times by up to 80 percent.
Nov 07, 2020
MilliporeSigma and Transcenta Collaborate to Advance Continuous Biomanufacturing, Make the ‘Facility of the Future’ a RealityMilliporeSigma and Transcenta, a global biotherapeutics company, have announced a strategic technology collaboration to implement continuous manufacturing for protein therapeutics.
Nov 06, 2020
MilliporeSigma to Collaborate with Donghao Lansheng to Pilot New Import Policy in ChinaMilliporeSigma today announced the signing of a Letter of Intent with Donghao Lansheng (Group) Co., Ltd.
Oct 18, 2020
MilliporeSigma Awards Grant to Combined Therapeutics for its Nucleic Acid Platform That, with Virotherapy, Targets Liver CancerMilliporeSigma today announced that Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of its 2020 Advance Biotech Grant Program.
Oct 12, 2020
MilliporeSigma’s New VirusExpress™ Platform Speeds Development of Cell and Gene TherapiesMilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform.
Oct 11, 2020
MilliporeSigma Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USAMilliporeSigma today announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada, and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California.
Oct 07, 2020
MilliporeSigma Supporting Innovation in China with D1Med CollaborationMilliporeSigma is collaborating with D1Med, a Shanghai-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.
Oct 07, 2020
MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Production PlantMilliporeSigma today celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany.
Oct 05, 2020
MilliporeSigma Inaugurates New, Upgraded Onsite Industrial Water Treatment PlantMilliporeSigma today inaugurated a new $14.4 million industrial water treatment plant at its Jaffrey, New Hampshire, location.
Sep 08, 2020
MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing ExpansionMilliporeSigma today announced a $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.
Sep 02, 2020
MilliporeSigma Supports Eijkman Institute to Expedite Covid-19 Vaccine Development ResearchMilliporeSigma today announced the donation of research instruments and materials worth IDR 1.2 billion (€ 74,000) to support the efforts of Eijkman Institute for Molecular Biology, Indonesia
Jul 29, 2020
MilliporeSigma’s DOZN™ Green Chemistry Tool Named Top Project of the Year by Environment + Energy Leader
MilliporeSigma today announced that it won a Top Project of the Year award from Environment + Energy Leader for the company’s DOZN™ system.
Jul 14, 2020
MilliporeSigma Invests $20 Million in New Switzerland LaboratoryMilliporeSigma has announced plans to build a new, $20 million laboratory facility in Buchs, Switzerland to support its rapidly growing reference materials business.
Jul 09, 2020
MilliporeSigma Opens its Largest M Lab™ Collaboration Center in ShanghaiMilliporeSigma today opened its M Lab™ Collaboration Center in Shanghai, the company’s largest of nine centers worldwide.
Jul 05, 2020
MilliporeSigma Announces VAR2 Pharmaceuticals as Winner of its Advance Biotech GrantMilliporeSigma today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program.
Jun 30, 2020
New Report Identifies Paths to Pandemic ResilienceA new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.
Jun 30, 2020
MilliporeSigma Advances Bioprocessing Capabilities with Raman Technology Sensor AcquisitionMilliporeSigma today enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring.
Jun 09, 2020
MilliporeSigma and 10x Genomics Launch Powerful New Option for CRISPR ResearchMilliporeSigma and 10x Genomics, Inc., a single cell and spatial genomics technologies company, today announced that they have developed a powerful new option for biological experiments.
May 26, 2020
MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19MilliporeSigma and Baylor College of Medicine today announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase 1 clinical trials.
May 11, 2020
MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 TechnologyMilliporeSigma today announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States.
Apr 30, 2020
MilliporeSigma Accelerates Readiness of Bioprocessing Facility of the FutureMilliporeSigma today unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation.
Apr 21, 2020
MilliporeSigma Boosts Commercial Viral Vector and Gene Therapy Manufacturing CapacityMilliporeSigma today announced a second Carlsbad, California-based facility for its BioReliance® viral and gene therapy service offering.
Apr 13, 2020
MilliporeSigma Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine ManufacturingMilliporeSigma and The Jenner Institute today announced that The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
Apr 06, 2020
MilliporeSigma Awarded Second U.S. Patent for CRISPR Gene-Editing TechnologyMilliporeSigma today announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology.
Mar 03, 2020
MilliporeSigma’s New LANEXO® System to Improve Scientists’ Productivity in the LabMilliporeSigma today launched its LANEXO® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Mar 02, 2020
MilliporeSigma’s New LANEXO® System to Improve Scientists’ Productivity in the Lab
MilliporeSigma today launched its LANEXO™ Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Feb 17, 2020
MilliporeSigma to Manufacture Elypta’s Liquid Biopsy KitsMilliporeSigma today announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits.
Feb 10, 2020
MilliporeSigma’s New BrightLab™ Cloud-hosted Software Brings IoT to R&DMilliporeSigma today introduced its BrightLab™ cloud-based inventory management and instrument connectivity platform for research scientists.
Jan 09, 2020
MilliporeSigma and CSIR-IMTECH Open High-tech Skill Development CenterMilliporeSigma today announced the opening of new, non-profit center where Indian students and researchers can learn the latest genome-editing and single-molecule biomolecule biomarker detection technologies from MilliporeSigma experts.
Dec 18, 2019
MilliporeSigma Licenses Foundational CRISPR Integration Technology to PromegaMilliporeSigma today announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, access to MilliporeSigma’s foundational CRISPR intellectual property.
Nov 25, 2019
Japan and Singapore Grant CRISPR Patents to MilliporeSigmaMilliporeSigma today announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed its patent application for the use of paired CRISPR nickases, bringing MilliporeSigma’s number of patents to 22 worldwide.
Nov 17, 2019
MilliporeSigma Expands in Gillingham, UK, Boosts Distribution CapabilitiesMilliporeSigma today announced the completion of a £9 million expansion to its Gillingham distribution center.
Nov 17, 2019
MilliporeSigma Wins R&D 100 Award for First-to-Market Biopharma Purification InnovationMilliporeSigma today announced it has received a prestigious R&D 100 Award for its Eshmuno® CP-FT Resin, a first-to-market product used in biopharmaceutical manufacturing.
Nov 11, 2019
MilliporeSigma Licenses CRISPR Gene-Editing Technology to EvotecMilliporeSigma today announced that it has signed a license agreement providing Evotec SE access to MilliporeSigma’s foundational CRISPR intellectual property.
Oct 18, 2019
MilliporeSigma Becomes the First to Use Acoustic Technology for Cell Therapy ManufacturingMilliporeSigma today announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing.
Sep 18, 2019
MilliporeSigma Launches First Flagship Store on Alibaba’s 1688.com to Improve the Customer ExperienceMilliporeSigma has launched its official flagship store on Alibaba’s 1688.com.
Sep 18, 2019
MilliporeSigma Expands BioReliance® Viral Clearance Offering in Singapore, Saving Customers TimeMilliporeSigma today announced an expansion of its Singapore biosafety testing laboratory services.
Aug 18, 2019
MilliporeSigma Granted 20 CRISPR Patents Total WorldwideMilliporeSigma today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma’s patent application claims covering CRISPR gene-editing technology.
Aug 05, 2019
MilliporeSigma Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the LabMilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and lon
Jul 23, 2019
MilliporeSigma to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics
MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for a collaboration on the development and manufacture of biologics for the treatment of solid tumors.
Jul 17, 2019
MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage InnovationMilliporeSigma and the Broad Institute of MIT and Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.
Jun 19, 2019
MilliporeSigma Introduces Mobile Laboratory to Promote Protein ResearchMilliporeSigma today announced a national campus tour in China for the company’s first mobile protein research laboratory.
Jun 19, 2019
Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named ‘Best Places to Work’ by Boston Business JournalMerck KGaA, Darmstadt, Germany, today announced that its Massachusetts-based business sectors, MilliporeSigma, EMD Serono and EMD Performance Materials, have been named to the Boston Business Journal’s annual “Best Places to Work".
May 29, 2019
MilliporeSigma Awards Grants to Biotechs Focused on Traumatic Brain Injury, Vaccine Development, and Chronic PainMilliporeSigma today announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center.
May 28, 2019
MilliporeSigma Announces Winners of School Science CompetitionMilliporeSigma today announced that students from St Aloysius’ College in Carrigtwohill have won the company’s 2019 School Science Competition, now in its 15th year.
May 26, 2019
MilliporeSigma Expands Cell Culture Media Production Facility in IrvineMilliporeSigma today announced the completion of a £2.7 million expansion to its Irvine biopharmaceutical production facility.
May 21, 2019
Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly EventMerck KGaA, Darmstadt, Germany, today hosted a panel discussion on the occasion of the 72nd World Health Assembly in Geneva, Switzerland.
May 19, 2019
MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and ManufacturingMilliporeSigma today announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative.
May 06, 2019
MilliporeSigma Announces Winner of First Retrosynthetic Reaction Prediction ContestMilliporeSigma today announced that MDL, a team from Beijing University, has won the company’s first Retrosynthetic Reaction Prediction Contest.
Apr 29, 2019
MilliporeSigma and India’s Food Safety and Standards Authority Partner on Skill Development in Food SafetyMilliporeSigma today announced the handover of a fully equipped microbiological testing laboratory to the Food Safety and Standards Authority of India (FSSAI).
Apr 23, 2019
MilliporeSigma Introduces New Greener Solvent, Cyrene™MilliporeSigma today launched Cyrene™ — a sustainable dipolar aprotic solvent, produced in two steps from a renewable cellulose source.
Apr 03, 2019
MilliporeSigma Recognized with INTERPHEX Exhibitor Award for Best New ProductMilliporeSigma today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next- generation bioprocessing.
Apr 01, 2019
MilliporeSigma Elevates its BioContinuum™ Platform Strategy to Deliver ‘ContiGuous’ BioprocessingMilliporeSigma today unveiled its BioContinuum™ Buffer Delivery Platform, a new building block in the BioContinuum™ Platform for next-generation bioprocessing, at INTERPHEX in New York City.
Mar 19, 2019
MilliporeSigma Opens First M Lab™ Collaboration Center in EuropeMilliporeSigma today officially opened its new M Lab™ Collaboration Center in Molsheim, France.
Mar 18, 2019
MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in ChinaMilliporeSigma today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
Mar 17, 2019
MilliporeSigma’s Milli-Q® Connect Combines Deep Water Purification Expertise with Cloud-based Digital TechnologyMilliporeSigma today announced a new cloud-based, remote lab water service and monitoring capability available on all Milli-Q® CLX 7000 clinical water purification systems.
Mar 13, 2019
Zhejiang University Joins MilliporeSigma’s CRISPR Core Partnership ProgramMilliporeSigma today announced a CRISPR core partnership with Zhejiang University in Hangzhou, China.
Mar 07, 2019
MilliporeSigma Brings Science Education to Students Across North America with Curiosity Cube® Mobile Science LabMilliporeSigma is igniting student interest in science with its third annual Curiosity Cube® mobile science lab tour.
Mar 04, 2019
MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing TechnologyMilliporeSigma today announced that the Canadian Patent Office has allowed MilliporeSigma’s patent application directed to the use of paired CRISPR nickases in eukaryotic cells.
Feb 18, 2019
MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing MethodMilliporeSigma today announced that the U.S. Patent and Trademark Office has issued a formal notice allowing MilliporeSigma’s patent application directed to its proxy-CRISPR technology.
Feb 03, 2019
MilliporeSigma Awards Grants to Biotechs Tackling Cancer and Cardiovascular DiseaseMilliporeSigma today announced the winners of its Advance Biotech Grant program in Europe. The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market.
Jan 14, 2019
MilliporeSigma Wins Life Science Industry Award® for Best Use of Social MediaMilliporeSigma today announced that it has been recognized by BioInformatics LLC with a 2018 Life Science Industry Award® for best use of social media.
Dec 18, 2018
MilliporeSigma Collaborates with Kuraray to Improve Drug DeliveryMilliporeSigma today announced it has extended and expanded its collaboration with Kuraray Europe to exclusively supply pharmaceutical polyvinyl alcohol (PVA) grades and improvements to benefit the pharmaceutical market.
Dec 10, 2018
MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent ModelsMilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
Mar 23, 2018
To continue reading please sign in or create an account.
Don't Have An Account?